Topic

Articles

Lincoln Pharmaceuticals has received a patent, which is valid for 20 years, from the Government of India for its liquid diclofenac metered-dose rectal spray.

Lincoln Pharmaceuticals Receives Patent for Novel Diclofenac Solution

A second lawsuit has been filed by Centrient Pharmaceuticals India in the High Court of Delhi in New Delhi against Dalas Biotech for patent infringement.

Centrient Pharmaceuticals Files Second Lawsuit Against Dalas Biotech

Takeda Pharmaceutical Company has acquired an exclusive global license from COUR Pharmaceuticals for the development and commercialization of an investigational celiac disease therapy.

Takeda Acquires Global License for Investigational Celiac Disease Therapy

Agnes Shanley is senior editor of Pharmaceutical Technology.

The agency seeks comments on a draft guidance designed to make the process conform to its original intent as a communication tool, rather than a roadblock to competition and innovation. 

Revamping the Citizen’s Petition Process for FDA

A District Court for the US District of Delaware has ruled in favor of Sanofi and Regeneron in the patent case targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

US Court Rules in Favor of Sanofi and Regeneron in Praluent Patent Case

A New Jersey court upheld the validity of patent claims for Amgen’s anti-inflammatory blockbuster biologic, Enbrel (etanercept).

Amgen Wins Enbrel Patent Case, Sandoz to Appeal Ruling

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

A risk-based approach to CMC enables drug sponsors to focus on clinical and manufacturing development paths.

Balancing CMC Priorities

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Europe has introduced a waiver for supplementary protection certificates, polarizing opinions throughout the industry. In this interview, the SPC waiver and its implications for European pharma are discussed.


The Great Divide? Implications of the SPC Waiver

AbbVie grants Boehringer Ingelheim a non-exclusive license to its intellectual property for Humira (adalimumab) in the United States.

Boehringer Ingelheim Humira US Patent Dispute Resolved

The new automated cloud-based tool allows for the design of targeted single-cell DNA custom panels.

Intellectual Property & Patents